Rabeprazole

Standard adult dosages for rabeprazole vary depending on the condition being treated. According to clinical guidelines:

• Erosive GERD: The typical dose is 20 mg taken once daily for 4 to 8 weeks. If healing is not achieved, an additional 8-week course may be considered by a physician.
• Maintenance of GERD Healing: 20 mg once daily. Studies have demonstrated safety and efficacy for up to 12 months of continuous use.
• Symptomatic GERD: 20 mg once daily for 4 weeks. If symptoms do not resolve, further diagnostic testing may be required.
• Duodenal Ulcers: 20 mg once daily after the morning meal for up to 4 weeks.
• H. pylori Eradication: 20 mg twice daily (every 12 hours) combined with amoxicillin 1000 mg and clarithromycin 500 mg for 7 to 14 days.
• Zollinger-Ellison Syndrome: The starting dose is usually 60 mg once daily, which may be adjusted upward to 100 mg daily or 60 mg twice daily based on patient response.

Rabeprazole is FDA-approved for the treatment of GERD in pediatric patients aged 1 year and older.

• Children 1 to 11 years (less than 15 kg): 5 mg or 10 mg once daily for up to 12 weeks.
• Children 1 to 11 years (15 kg or more): 10 mg once daily.
• Adolescents (12 years and older): 20 mg once daily for up to 8 weeks.

For children, the delayed-release sprinkle capsules are often preferred as they can be opened and sprinkled on soft food.

Renal Impairment

No dosage adjustment is typically required for patients with renal insufficiency or those undergoing hemodialysis. The pharmacokinetic profile of rabeprazole is not significantly altered by impaired kidney function.

Hepatic Impairment

In patients with mild to moderate hepatic impairment, the half-life of rabeprazole is increased. While no specific dose adjustment is mandated for mild cases, healthcare providers should exercise caution and use the lowest effective dose in patients with severe liver cirrhosis.

Elderly Patients

Clinical studies have shown that no dosage adjustments are necessary for the elderly. However, older adults may be at higher risk for certain side effects, such as bone fractures or B12 deficiency, and should be monitored accordingly.

To ensure maximum efficacy and safety, patients should adhere to the following instructions:

1. 1Timing: For most conditions, rabeprazole should be taken at least 30 minutes before the first meal of the day (usually breakfast). For H. pylori eradication, it is taken twice daily with meals.
2. 2Whole Ingestion: Delayed-release tablets must be swallowed whole. Do not crush, chew, or split the tablets, as this destroys the enteric coating and allows stomach acid to inactivate the medication.
3. 3Sprinkle Capsules: If using the sprinkle formulation, the capsule can be opened and the granules mixed with a small amount of soft food (like applesauce or yogurt) or liquid. The mixture should be consumed immediately without chewing the granules.
4. 4Storage: Store the medication at room temperature (59°F to 86°F) in a dry place, away from direct sunlight and moisture.

If you miss a dose of rabeprazole, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once to make up for a missed one.

There is limited experience with rabeprazole overdose. Reports of accidental ingestion of up to 80 mg have shown no clinical signs of toxicity. However, a massive overdose could lead to severe electrolyte imbalances or excessive acid suppression. Signs of overdose may include confusion, headache, drowsiness, or dry mouth. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this may lead to a return of symptoms or "rebound" acid secretion.

While rabeprazole is generally well-tolerated, some patients may experience mild side effects. These often resolve as the body adjusts to the medication. Common side effects reported in clinical trials include:

• Headache: The most frequently reported side effect. It is typically mild and transient.
• Nausea and Vomiting: Some patients may feel slight stomach upset shortly after taking the medication.
• Diarrhea: This is common with all PPIs. If diarrhea becomes severe or watery, it may indicate a more serious condition (see Serious Side Effects).
• Abdominal Pain: General discomfort or cramping in the stomach area.
• Flatulence: Increased gas or bloating.
• Infection: In pediatric populations, an increased incidence of upper respiratory tract infections has been noted.

These side effects occur in a smaller percentage of the population but are still documented:

• Dizziness: A feeling of lightheadedness or vertigo.
• Rash: Minor skin irritations or itching.
• Constipation: Difficulty with bowel movements.
• Insomnia: Trouble falling or staying asleep.
• Dry Mouth: A decrease in saliva production.
• Myalgia: General muscle aches or pains without a clear cause.

Rare but documented side effects include:

• Gynaecomastia: Enlargement of breast tissue in males.
• Leukopenia or Thrombocytopenia: A decrease in white blood cells or platelets, which may increase infection or bleeding risk.
• Hepatitis: Inflammation of the liver, often marked by yellowing of the skin or eyes (jaundice).
• Interstitial Nephritis: A rare kidney inflammation that can lead to kidney failure.

> Warning: Stop taking Rabeprazole and call your doctor immediately if you experience any of these serious symptoms.

1. 1Severe Allergic Reactions (Anaphylaxis): Symptoms include hives, swelling of the face, lips, or throat, and difficulty breathing. This is a medical emergency.
2. 2Clostridioides difficile-Associated Diarrhea (CDAD): PPIs like rabeprazole may increase the risk of C. diff infection. Symptoms include watery stools, stomach pain, and fever that does not go away.
3. 3Hypomagnesemia (Low Magnesium): Long-term use (usually over one year) can cause magnesium levels to drop. Symptoms include tremors, seizures, muscle spasms (tetany), and irregular heartbeat (arrhythmias).
4. 4Systemic Lupus Erythematosus (SLE) or Subacute Cutaneous Lupus Erythematosus (SCLE): PPIs have been linked to the development or worsening of autoimmune lupus. Look for joint pain or a skin rash on the cheeks or arms that worsens in sunlight.
5. 5Acute Tubulointerstitial Nephritis: Signs include decreased urine output, blood in the urine, or sudden weight gain from fluid retention.

Extended use of rabeprazole (months to years) carries specific risks that patients and providers must monitor:

• Bone Fractures: Long-term, high-dose PPI therapy is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine. This is likely due to decreased calcium absorption.
• Vitamin B12 Deficiency: Gastric acid is required for the absorption of Vitamin B12 (cyanocobalamin) from food. Chronic acid suppression can lead to deficiency, resulting in anemia or nerve damage.
• Fundic Gland Polyps: Long-term use may lead to the development of small, benign growths in the upper part of the stomach. These are usually asymptomatic and found during endoscopy.
• Gastric Carcinoid Tumors: While primarily seen in animal studies with extreme doses, long-term hypergastrinemia (elevated gastrin levels) is a theoretical risk being monitored in humans.

No FDA black box warnings currently exist for Rabeprazole. However, the FDA has issued several safety communications regarding the risks of long-term PPI use, including the risk of fractures and C. diff infections, which are reflected in the standard warning sections of the drug's labeling.

Report any unusual symptoms or changes in your health to your healthcare provider immediately. Regular monitoring of magnesium and B12 levels may be recommended for those on long-term therapy.

Rabeprazole is a potent medication that significantly alters the chemical environment of the stomach. While effective, it must be used with caution. Patients should be aware that symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy. In older patients or those with alarming symptoms (e.g., significant unintentional weight loss, recurrent vomiting, dysphagia, hematemesis, or melena), the possibility of malignancy should be excluded before starting PPI therapy.

There are currently no FDA black box warnings for Rabeprazole. It is considered safe for its approved indications when used as directed by a healthcare professional.

Allergic Reactions / Anaphylaxis Risk

Patients with a known hypersensitivity to rabeprazole, other substituted benzimidazoles (such as omeprazole, lansoprazole, pantoprazole, or esomeprazole), or any component of the formulation should not take this medication. Cross-sensitivity among this class of drugs is common. Serious skin reactions, including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported rarely.

Organ-Specific Risks

• Renal Effects: Acute tubulointerstitial nephritis has been observed in patients taking PPIs. This can occur at any point during therapy and is generally attributed to an idiopathic hypersensitivity reaction. If this occurs, the drug should be discontinued immediately.
• Hepatic Effects: While rabeprazole is primarily metabolized in the liver, significant hepatotoxicity is rare. However, in patients with severe hepatic impairment, the drug's half-life is doubled, necessitating careful monitoring.
• Bone Health: Increased risk of hip, wrist, or spine fractures has been noted, especially in patients receiving high doses or long-term (one year or longer) therapy. Patients should use the lowest dose and shortest duration of therapy appropriate to the condition being treated.

Vitamin and Mineral Malabsorption

• Hypomagnesemia: Low serum magnesium may occur after prolonged use. In some cases, this requires magnesium replacement and discontinuation of the PPI.
• Vitamin B12 Deficiency: Daily treatment with acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin.

For most short-term users, routine lab monitoring is not required. However, for those on long-term therapy or with underlying conditions, healthcare providers may monitor:

• Serum Magnesium: Prior to starting and periodically during long-term treatment.
• Vitamin B12 Levels: Especially in patients with low baseline stores or those on therapy for over 3 years.
• INR/Prothrombin Time: In patients also taking warfarin, as PPIs can occasionally interfere with warfarin metabolism.
• Bone Density: In patients at high risk for osteoporosis.

Rabeprazole is unlikely to impair the ability to drive or operate machinery. However, rare side effects such as dizziness or somnolence (drowsiness) have been reported. Patients should observe how they react to the medication before engaging in activities requiring mental alertness.

While there is no direct chemical interaction between rabeprazole and alcohol, alcohol consumption can increase gastric acid production and irritate the stomach lining. This may worsen the symptoms of GERD or peptic ulcers, effectively counteracting the benefits of the medication. It is generally advised to limit alcohol intake while treating acid-related disorders.

Abruptly stopping rabeprazole after long-term use can sometimes lead to "rebound acid hypersecretion." This occurs because the body has overcompensated for the drug's acid-blocking effects by producing more gastrin. When the drug is stopped, acid production may temporarily surge, causing symptoms to return more severely than before. If you have been on rabeprazole for a long time, your doctor may recommend tapering the dose.

> Important: Discuss all your medical conditions, including any history of liver disease or osteoporosis, with your healthcare provider before starting Rabeprazole.

Certain medications should never be taken with rabeprazole due to the risk of severe adverse effects or complete loss of drug efficacy:

• Rilpivirine-containing products: PPIs significantly reduce the plasma concentrations of rilpivirine (an HIV medication), which can lead to loss of virologic response and drug resistance. This combination is strictly contraindicated.
• Nelfinavir: Similar to rilpivirine, nelfinavir concentrations are significantly decreased when taken with PPIs, reducing its effectiveness in treating HIV.

• Methotrexate: Case reports and pharmacokinetic studies suggest that concomitant use of PPIs with methotrexate (primarily at high doses) may elevate and prolong serum levels of methotrexate and its metabolite, potentially leading to methotrexate toxicities (such as kidney damage or low blood counts).
• Warfarin: There have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. This can increase the risk of abnormal bleeding. Patients should be monitored closely for changes in coagulation parameters.
• Digoxin: Because rabeprazole increases gastric pH, the absorption of digoxin may increase, potentially leading to digoxin toxicity. Monitoring of serum digoxin levels is recommended.

• pH-Dependent Drugs: The absorption of certain drugs depends on the presence of gastric acid. By increasing the pH, rabeprazole may decrease the absorption of:
• Ketoconazole and Itraconazole (antifungals)
• Iron salts (supplements)
• Erlotinib and Gefitinib (cancer medications)
• Mycophenolate Mofetil (immunosuppressant)
• Clopidogrel: While the interaction is more pronounced with omeprazole, some studies suggest PPIs may slightly reduce the conversion of clopidogrel to its active metabolite via CYP2C19 inhibition. The clinical significance for rabeprazole is considered low, but caution is advised in high-risk cardiac patients.

• Timing with Food: While the AUC (total absorption) of rabeprazole is not significantly affected by food, taking the medication with a high-fat meal can delay absorption by 1.5 hours or more. For conditions like GERD, it is most effective when taken 30 minutes before a meal to ensure the drug is active when the proton pumps are most stimulated by eating.
• Dairy: There are no known significant interactions with dairy products.

• St. John's Wort: This herbal supplement is a potent inducer of CYP3A4 and CYP2C19. It may significantly decrease the plasma levels of rabeprazole, rendering the treatment less effective.
• Ginkgo Biloba: May potentially interfere with the metabolism of drugs processed by the CYP system, though the clinical impact on rabeprazole is usually minimal.

• Chromogranin A (CgA) Levels: Increased CgA levels may occur secondary to PPI-induced hypergastrinemia. This can cause false-positive results in diagnostic tests for neuroendocrine tumors. PPIs should be temporarily stopped at least 14 days before CgA testing.
• Urine Screening for THC: Some PPIs have been reported to cause false-positive urine screening tests for tetrahydrocannabinol (THC). If a positive result occurs, a more specific confirmatory test should be performed.
• Secretin Stimulation Test: PPIs can cause a false-positive result in this test for gastrinoma. Treatment should be discontinued at least 3 days prior to the test.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter drugs, to prevent dangerous interactions.

Rabeprazole must NEVER be used in the following circumstances:

• Hypersensitivity: Any patient with a known allergy to rabeprazole sodium or any of the inactive ingredients in the formulation (such as mannitol, magnesium stearate, or ethylcellulose). An allergic reaction can manifest as skin rashes, swelling, or life-threatening anaphylaxis.
• Substituted Benzimidazole Allergy: Patients who have had an allergic reaction to other PPIs (e.g., omeprazole, lansoprazole, pantoprazole, esomeprazole) should not take rabeprazole. The chemical structures are similar enough that cross-reactivity is highly likely.
• Concomitant Rilpivirine Use: As noted in the interactions section, the use of rilpivirine-containing products is an absolute contraindication due to the risk of HIV treatment failure.

Conditions requiring a careful risk-benefit analysis by a healthcare provider include:

• Severe Hepatic Cirrhosis: Because the liver is the primary site of metabolism, severe impairment can lead to significantly elevated drug levels. While not an absolute contraindication, it requires extreme caution and lower dosing.
• Osteoporosis: Patients already at high risk for bone fractures should be evaluated carefully, as PPIs can further decrease calcium absorption and bone mineral density.
• Hypomagnesemia: Patients with existing low magnesium levels should have these corrected before starting rabeprazole, as the drug can worsen the condition.
• Pregnancy and Lactation: In the absence of definitive human data, use during pregnancy or breastfeeding is generally reserved for cases where the benefits clearly outweigh the potential risks to the fetus or infant.

There is a high degree of cross-sensitivity between rabeprazole and other proton pump inhibitors. If a patient has experienced an adverse immune-mediated reaction (like interstitial nephritis or a severe rash) with one PPI, they are likely to experience it with rabeprazole. However, patients who experience simple side effects like headache or nausea with one PPI may sometimes tolerate rabeprazole better due to its slightly different metabolic pathway.

> Important: Your healthcare provider will evaluate your complete medical history, including any previous drug allergies, before prescribing Rabeprazole.

FDA Pregnancy Category: B (Prior System).

There are no adequate and well-controlled studies of rabeprazole in pregnant women. Animal reproduction studies using rats and rabbits at doses up to 400 times the human dose did not show evidence of harm to the fetus or impaired fertility. However, because animal studies are not always predictive of human response, rabeprazole should be used during pregnancy only if clearly needed. It is generally recommended to avoid use during the first trimester unless the clinical benefit is substantial. Healthcare providers typically prefer lifestyle modifications or antacids as first-line treatments for pregnancy-related reflux.

It is not known whether rabeprazole is excreted in human breast milk. However, many drugs are excreted in milk, and animal studies have shown that rabeprazole is secreted in the milk of lactating rats. Because of the potential for serious adverse reactions in nursing infants from rabeprazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Rabeprazole is approved for the treatment of GERD in children 1 year of age and older. It has not been studied or approved for children under the age of 1. In pediatric trials, the side effect profile was similar to that seen in adults, though there was a higher incidence of abdominal pain and upper respiratory tract infections. The long-term effects of acid suppression on growth and development in children are not fully known, so use should be limited to the shortest duration necessary.

In clinical trials, no overall differences in safety or effectiveness were observed between elderly subjects (65 years and older) and younger subjects. However, the elderly are more susceptible to certain complications of long-term PPI use:

• Fracture Risk: Increased risk of hip fractures due to age-related bone density loss.
• Nutritional Deficiencies: Higher likelihood of B12 or magnesium deficiency.
• Polypharmacy: Elderly patients are often on multiple medications (like diuretics or digoxin), increasing the risk of drug-drug interactions.

Pharmacokinetic studies in patients with stable end-stage renal failure receiving maintenance hemodialysis showed no clinically significant changes in the disposition of rabeprazole. No dosage adjustment is necessary for patients with any degree of renal impairment.

In patients with mild to moderate hepatic impairment, the AUC (area under the curve) of rabeprazole is approximately doubled compared to healthy volunteers. While dose adjustments are not strictly required for mild cases, patients with severe liver disease (Child-Pugh Class C) should be monitored very closely for adverse effects. There is limited data on the use of rabeprazole in patients with severe hepatic failure.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Rabeprazole is a gastric proton pump inhibitor. It suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. This enzyme is known as the "proton pump," and it is responsible for the final step of acid secretion, exchanging potassium ions for hydrogen ions (protons) into the stomach lumen. Rabeprazole is a weak base and is rapidly absorbed. Because it is acid-labile, it is formulated as enteric-coated tablets. Once absorbed, it concentrates in the acidic environment of the parietal cells, where it is converted to its active sulfonamide form. This active form binds covalently to the cysteine residues of the proton pump, resulting in irreversible inhibition of acid secretion.

Following oral administration of 20 mg of rabeprazole, the onset of the antisecretory effect occurs within one hour. The maximum effect occurs within two to four hours. Inhibition of acid secretion is approximately 88% after the first dose and reaches a steady state after three to four days of once-daily dosing. The duration of the inhibitory effect is long; acid secretion remains suppressed for up to 48 hours after a single dose, despite the drug's short plasma half-life.

| Parameter | Value |

|---|---|

| Bioavailability | ~52% (due to first-pass metabolism) |

| Protein Binding | 96.3% (primarily to albumin) |

| Half-life | 1 - 2 hours (plasma); effect lasts 24-48 hours |

| Tmax | 2.0 - 5.0 hours (delayed by food) |

| Metabolism | Primarily non-enzymatic; also CYP2C19 and CYP3A4 |

| Excretion | Renal 90%, Fecal 10% |

• Molecular Formula: C18H20N3NaO3S
• Molecular Weight: 381.43 g/mol (as sodium salt)
• Solubility: Very soluble in water and methanol; freely soluble in ethanol.
• Structure: Rabeprazole is a substituted benzimidazole. It consists of a benzimidazole ring linked to a pyridine ring by a methylsulfinyl group. This structure allows it to function as a prodrug that is activated only in highly acidic environments.

Rabeprazole is classified as a Proton Pump Inhibitor (PPI). It is part of a therapeutic class that includes omeprazole, lansoprazole, pantoprazole, and esomeprazole. Within this class, rabeprazole is noted for its rapid onset of action and its metabolism pathway, which is less dependent on the CYP2C19 enzyme than some of its counterparts.